Amneal Pharmaceuticals, Inc.

AMRX · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders52.1%

Institutions48.4%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$3.02B	$2.79B	$2.39B	$2.21B	$2.09B	$1.99B	$1.63B	$1.66B	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$1.91B	$1.77B	$1.57B	$1.42B	$1.30B	$1.33B	$1.15B	$946.59M	–
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	$1.11B	$1.02B	$820.57M	$784.71M	$768.97M	$628.39M	$353.00M	$716.40M	–
Gross profit as a percentage of revenue.	36.9%	36.5%	34.3%	35.5%	36.7%	31.5%	21.7%	43.1%	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$394.10M	$249.33M	$204.37M	-$94.93M	$152.72M	$91.16M	-$248.68M	-$19.67M	–
Operating income as a percentage of revenue.	13.1%	8.9%	8.5%	-4.3%	7.3%	4.6%	-15.3%	-1.2%	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$55.88M	$43.01M	$35.27M	-$125.24M	$9.55M	$0	$0	-$148.81M	–
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.23	$-0.38	$-0.48	$-0.86	$0.07	$0.62	$-2.74	$0.00	–
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.22	$-0.38	$-0.48	$-0.86	$0.07	$0.61	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$282.03M	$110.55M	$91.54M	$25.98M	$247.79M	$341.38M	$151.20M	$213.39M	–
Everything the company owns that has value — cash, property, inventory, investments, and more.	$3.68B	$3.50B	$3.47B	$3.80B	$3.94B	$4.01B	$3.67B	$4.35B	$0
All of the company's interest-bearing borrowings, short and long term combined.	$2.57B	$2.39B	$2.42B	$2.62B	$2.71B	$2.74B	$2.61B	$2.63B	–
Everything the company owes — debt, unpaid bills, and other obligations.	–	–	–	–	–	–	–	–	$0
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$70.79M	-$109.27M	$19.78M	$298.42M	$360.34M	$303.27M	$232.01M	$504.75M	$0

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$339.99M	$295.10M	$345.58M	$65.10M	$241.82M	$379.00M	$1.71M	$250.23M	–
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$70.06M	$51.92M	$43.22M	$46.41M	$47.73M	$56.45M	$47.18M	$83.09M	–
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$269.93M	$243.18M	$302.36M	$18.69M	$194.09M	$322.56M	-$45.48M	$167.14M	–

	You	Peer avg
P/E	36.3	14.2
Revenue Growth	+9.9%	+15.0%
ROE	613.0%	-4.2%

Amneal Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison